Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LNCB 74

Next Previous
Drug Profile

LNCB 74

Alternative Names: B7-H4 targeting antibody drug conjugate - LigaChem Biosciences/NextCure; LCB-41A; LNCB-74

Latest Information Update: 17 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LegoChem Biosciences; NextCure
  • Developer LigaChem Biosciences; NextCure
  • Class Antibodies; Antineoplastics; Benzodiazepines; Drug conjugates; Immunotoxins; Pyrroles
  • Mechanism of Action DNA cross linking agents; DNA damage stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Breast cancer; Endometrial cancer; Ovarian cancer
  • Research Cancer; Haematological malignancies

Most Recent Events

  • 10 Jan 2025 Phase-I clinical trials in Solid tumours (Monotherapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in USA (IV) (NCT06774963)
  • 10 Dec 2024 US FDA approves IND application for phase I trial for LNCB 74 in Cancer
  • 10 Dec 2024 Early research in Haematological malignancies in USA, South Korea (Parenteral) before December 2024 (LegoChem Biosciences pipeline, October 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top